RETNLB and myeloid sarcoma: In the culture of corticostriatal slices obtained from mice with experimental autoimmune encephalomyelitis (EAE) as a popular animal model of MS [61,62], ozanimod (RPC1063, Zeposia®, Bristol Myers Squibb), a recently developed drug to treat MS by targeting S1P1 and S1P5 [63], can attenuate M1 microglial activation, as evidenced by reduced mRNA expression levels of Iba1, iNOS, IL-1β, and TNF-α, while it induces M2 microglial activation, as evidenced by increased mRNA expression levels of Found in Inflammatory Zone 1 (FIZZ1) [63].